全球生物科技的研發得耗費龐大的時間與資金，在生物科技之中，尤以製藥是最需要上下游網絡共同合作，所以本研究主要以生物科技產業中的製藥為研究標的，研究對象選擇全球前33家生技產業，並根據先前學者分析構建了兩階段網絡模型，接著透過行動者網絡理論觀點分別加入產學合作密度以及外部法人投資並進一步探討生物科技兩階段效率。接著對全球前33家生技企業進行分析，得知其相關效率值並對此給予建議。最後運用BCG矩陣可得知生技企業應藉由專利技術合作運用，補強在第一階段研發的不足；另外，於第二階段應讓投資人多瞭解公司運作及研發項目，進而提高公司第二階段相對價值。最後，對生技產業未來趨勢及研發策略提出相關之建議。;The development of global biotechnology R&D has consumed enormous time and money. This study is mainly focus on the research and development efficiency of the top 33 biotechnology industries in the world. In this study, a two-stage network model was constructed based on previous scholars′ analysis, and the industry-university cooperation density and external corporate investment were added respectively through the Actor-Network Theory to further explore the efficiency of biotechnology research and development. Then, we analyzed the top 33 biotech companies in the world and found out their relative efficiency values. Lastly, Using the BCG matrix to learn that biotechnology companies reinforce the shortcomings in the first phase of research and development through patent and technology collaboration reinforcement. In addition, in the second stage, investors should be informed more about company operations and research and development projects, thereby increasing the relative value of the company′s second phase. Finally, infused with constructional suggestions on future research and development strategies are proposed to improve the efficiency of the biotechnology industry.
